DK1601689T3 - Oprensningsfremgangsmåde for bakterielt cytolysin - Google Patents

Oprensningsfremgangsmåde for bakterielt cytolysin

Info

Publication number
DK1601689T3
DK1601689T3 DK04719447T DK04719447T DK1601689T3 DK 1601689 T3 DK1601689 T3 DK 1601689T3 DK 04719447 T DK04719447 T DK 04719447T DK 04719447 T DK04719447 T DK 04719447T DK 1601689 T3 DK1601689 T3 DK 1601689T3
Authority
DK
Denmark
Prior art keywords
purification procedure
bacterial cytolysin
cytolysin purification
bacterial
procedure
Prior art date
Application number
DK04719447T
Other languages
English (en)
Inventor
Ralph Biemans
Emmanuel Mertens
Carine Goraj
Anne Vandercammen
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0305791A external-priority patent/GB0305791D0/en
Priority claimed from GB0305792A external-priority patent/GB0305792D0/en
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Application granted granted Critical
Publication of DK1601689T3 publication Critical patent/DK1601689T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK04719447T 2003-03-13 2004-03-11 Oprensningsfremgangsmåde for bakterielt cytolysin DK1601689T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0305791A GB0305791D0 (en) 2003-03-13 2003-03-13 Detoxification process
GB0305792A GB0305792D0 (en) 2003-03-13 2003-03-13 Purification Process
PCT/EP2004/002641 WO2004081515A2 (en) 2003-03-13 2004-03-11 Purification process for bacterial cytolysin

Publications (1)

Publication Number Publication Date
DK1601689T3 true DK1601689T3 (da) 2008-03-25

Family

ID=32992596

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04719447T DK1601689T3 (da) 2003-03-13 2004-03-11 Oprensningsfremgangsmåde for bakterielt cytolysin

Country Status (23)

Country Link
US (3) US8084235B2 (da)
EP (1) EP1601689B1 (da)
JP (2) JP4597123B2 (da)
KR (1) KR101052996B1 (da)
CN (1) CN101818185B (da)
AU (2) AU2004219910B2 (da)
BR (1) BRPI0408094A (da)
CA (2) CA2812817C (da)
CY (1) CY1107134T1 (da)
DE (1) DE602004010376T2 (da)
DK (1) DK1601689T3 (da)
EG (1) EG24449A (da)
ES (1) ES2295836T3 (da)
HK (1) HK1086013A1 (da)
IL (1) IL210984A0 (da)
IS (1) IS2587B (da)
MA (1) MA27666A1 (da)
MX (1) MXPA05009579A (da)
NO (1) NO336672B1 (da)
NZ (1) NZ541969A (da)
PT (1) PT1601689E (da)
RU (1) RU2340627C2 (da)
WO (1) WO2004081515A2 (da)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2340627C2 (ru) 2003-03-13 2008-12-10 ГлаксоСмитКлайн Байолоджикалз с.а. Способ очистки бактериального цитолизина
GB0421083D0 (en) * 2004-09-22 2004-10-27 Glaxosmithkline Biolog Sa Purification process
BRPI0609711B8 (pt) 2005-03-23 2021-05-25 Oculus Innovative Sciences Inc uso de uma solução aquosa com potencial redutivo oxidativo (orp)
PT2351578T (pt) 2005-06-27 2017-04-07 Glaxosmithkline Biologicals Sa Processo para o fabrico de vacinas
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
DK3017827T3 (da) 2005-12-22 2019-02-18 Glaxosmithkline Biologicals Sa Pneumokok-polysaccharidkonjugat-vaccine
US8147444B2 (en) 2006-01-20 2012-04-03 Oculus Innovative Sciences, Inc. Methods of treating or preventing peritonitis with oxidative reductive potential water solution
ES2387582T3 (es) 2006-09-07 2012-09-26 Glaxosmithkline Biologicals S.A. Vacuna de combinación con cantidades reducidas del antígeno del virus de la polio
EP2144924B1 (en) * 2007-04-16 2016-05-11 MinervaX Aps Fusion protein vaccine
EP2142211A1 (en) 2007-05-02 2010-01-13 GlaxoSmithKline Biologicals S.A. Vaccine
PL2167121T3 (pl) 2007-06-26 2016-01-29 Glaxosmithkline Biologicals Sa Szczepionka zawierająca koniugaty polisacharydu otoczkowego streptococcus pneumoniae
ES2678694T3 (es) 2008-04-16 2018-08-16 Glaxosmithkline Biologicals Sa Vacuna
EA201100268A1 (ru) * 2008-08-28 2011-10-31 Глаксосмитклайн Байолоджикалс С.А. Вакцина
DK2424562T3 (da) 2009-04-30 2015-12-07 Coley Pharm Group Inc Pneumokokvaccine og anvendelser deraf
US8668911B2 (en) 2009-05-14 2014-03-11 The Regents Of The University Of Michigan Streptococcus vaccine compositions and methods of using the same
CN102480972B (zh) 2009-06-15 2014-12-10 奥古露丝创新科学公司 含有次氯酸的溶液及其使用方法
MX2012002639A (es) 2009-09-03 2012-03-14 Pfizer Vaccines Llc Vacuna de pcsk9.
LT2493498T (lt) 2009-10-30 2017-05-25 Glaxosmithkline Biologicals Sa Staphylococcus aureus 5 tipo ir 8 tipo kapsulinių sacharidų gryninimas
GB201003924D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
US20140004142A1 (en) 2011-03-02 2014-01-02 Pfizer Inc. Pcsk9 vaccine
PT3549949T (pt) * 2011-04-22 2024-02-02 Wyeth Llc Composições relacionadas com uma toxina de clostridium difficile mutante e métodos da mesma
MX339058B (es) 2011-05-17 2016-05-09 Glaxosmithkline Biolog Sa Vacuna contra streptococcus pneumoniae.
JP5854537B2 (ja) * 2012-09-19 2016-02-09 国立大学法人大阪大学 肺炎球菌表面タンパク質ａを含む肺炎球菌ワクチン
RU2615446C2 (ru) * 2012-11-30 2017-04-04 Байонир Корпорейшн Прибор для автоматизированного бесклеточного получения белков и способ получения белков с применением данного прибора
WO2015095868A1 (en) 2013-12-20 2015-06-25 Wake Forest University Health Sciences Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
BR122023022294A2 (pt) 2014-01-21 2023-12-12 Pfizer Inc. Uso de uma composição imunogênica que compreende um conjugado imunogênico compreendendo um polissacarídeo capsular isolado de streptococcus pneumoniae do sorotipo 15b
MX2016009470A (es) 2014-01-21 2017-01-18 Pfizer Composiciones inmunogenicas que comprenden antigenos sacaridos capsulares conjugados y usos de los mismos.
US10105431B2 (en) 2014-01-21 2018-10-23 Pfizer Inc. Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
JP2017505792A (ja) 2014-02-14 2017-02-23 ファイザー・インク 免疫原性糖タンパク質コンジュゲート
US10653764B2 (en) 2015-01-15 2020-05-19 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
US9218427B1 (en) * 2015-01-21 2015-12-22 Maana, Inc. Dynamic semantic models having multiple indices
EP3283102A4 (en) * 2015-04-16 2018-10-03 Inventprise, LLC. Bordetella pertussis immunogenic vaccine compositions
KR102225282B1 (ko) 2015-07-21 2021-03-10 화이자 인코포레이티드 접합된 캡슐형 사카라이드 항원을 포함하는 면역원성 조성물, 그를 포함하는 키트 및 그의 용도
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
CA3005524C (en) 2015-11-20 2023-10-10 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
GB201603029D0 (en) * 2016-02-22 2016-04-06 Glaxosmithkline Biolog Sa Vaccine
US11224652B2 (en) 2016-08-05 2022-01-18 Sanofi Pasteur Inc. Multivalent pneumococcal polysaccharide-protein conjugate composition
CN109862908B (zh) 2016-08-05 2023-05-02 圣诺菲·帕斯图尔公司 多价肺炎球菌多糖-蛋白质缀合物组合物
WO2018102818A1 (en) * 2016-12-02 2018-06-07 President And Fellows Of Harvard College Processive template independent dna polymerase variants
EP3562503A2 (en) 2016-12-30 2019-11-06 Sutrovax, Inc. Polypeptide-antigen conjugates with non-natural amino acids
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
EP3570879B1 (en) 2017-01-20 2022-03-30 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
EP3576759A4 (en) 2017-01-31 2020-11-11 Merck Sharp & Dohme Corp. PROCESS FOR THE PREPARATION OF CAPSULE POLYSACCHARIDE PROTEIN CONJUGATES FROM STREPTOCOCCUS PNEUMONIAE SEROTYPE 19F
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
US10688170B2 (en) 2017-06-10 2020-06-23 Inventprise, Llc Multivalent conjugate vaccines with bivalent or multivalent conjugate polysaccharides that provide improved immunogenicity and avidity
JP7438102B2 (ja) 2017-09-07 2024-02-26 メルク・シャープ・アンド・ドーム・エルエルシー 肺炎球菌多糖体および免疫原性多糖体－キャリアタンパク質コンジュゲートでのその使用
CN111683678B (zh) 2017-12-06 2024-01-26 默沙东有限责任公司 包含肺炎链球菌多糖蛋白缀合物的组合物及其使用方法
BR112020015696A2 (pt) 2018-02-05 2020-12-08 Sanofi Pasteur, Inc. Composição de conjugado polissacarídeo-proteína pneumocócico multivalente
KR20200121822A (ko) 2018-02-05 2020-10-26 사노피 파스퇴르 인코포레이티드 다가 폐렴구균성 다당류-단백질 접합체 조성물
JP2021522213A (ja) 2018-04-18 2021-08-30 エスケー バイオサイエンス カンパニー リミテッド ストレプトコッカス・ニューモニエ莢膜多糖類及びその免疫原性接合体
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
CA3120922A1 (en) 2018-12-12 2020-06-18 Pfizer Inc. Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
JP2022513458A (ja) 2018-12-12 2022-02-08 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Ｏ－結合型グリコシル化のための修飾キャリアタンパク質
CA3123414A1 (en) 2018-12-19 2020-06-25 Merck Sharp & Dohme Corp. Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
JP7239509B6 (ja) 2019-02-22 2023-03-28 ファイザー・インク 細菌多糖類を精製するための方法
US20220184199A1 (en) 2019-04-10 2022-06-16 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
JP2022542316A (ja) 2019-07-31 2022-09-30 サノフィ パスツール インコーポレイテッド 多価肺炎球菌多糖体－タンパク質コンジュゲート組成物およびその使用方法
EP4051696A1 (en) 2019-11-01 2022-09-07 Pfizer Inc. Escherichia coli compositions and methods thereof
BR112022015796A2 (pt) 2020-02-21 2022-10-11 Pfizer Purificação de sacarídeos
CA3173729A1 (en) 2020-02-23 2021-08-26 Pfizer Inc. Escherichia coli compositions and methods thereof
WO2022084852A1 (en) 2020-10-22 2022-04-28 Pfizer Inc. Methods for purifying bacterial polysaccharides
MX2023004912A (es) 2020-10-27 2023-05-16 Pfizer Composiciones de escherichia coli y metodos de las mismas.
EP4240410A1 (en) 2020-11-04 2023-09-13 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
US20220202923A1 (en) 2020-12-23 2022-06-30 Pfizer Inc. E. coli fimh mutants and uses thereof
TW202245835A (zh) 2021-02-04 2022-12-01 美商默沙東有限責任公司 用於肺炎球菌結合物疫苗之奈米乳化液佐劑組合物
JP2024517780A (ja) 2021-05-03 2024-04-23 ファイザー・インク 細菌およびベータコロナウイルス感染症に対するワクチン接種
WO2022234416A1 (en) 2021-05-03 2022-11-10 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections
TW202306969A (zh) 2021-05-28 2023-02-16 美商輝瑞大藥廠 包含結合之莢膜醣抗原的免疫原組合物及其用途
US20220387613A1 (en) 2021-05-28 2022-12-08 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2023135515A1 (en) 2022-01-13 2023-07-20 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2023161817A1 (en) 2022-02-25 2023-08-31 Pfizer Inc. Methods for incorporating azido groups in bacterial capsular polysaccharides
WO2023218322A1 (en) 2022-05-11 2023-11-16 Pfizer Inc. Process for producing of vaccine formulations with preservatives
WO2024084397A1 (en) 2022-10-19 2024-04-25 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections
WO2024110827A1 (en) 2022-11-21 2024-05-30 Pfizer Inc. Methods for preparing conjugated capsular saccharide antigens and uses thereof
WO2024110839A2 (en) 2022-11-22 2024-05-30 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024116096A1 (en) 2022-12-01 2024-06-06 Pfizer Inc. Pneumococcal conjugate vaccine formulations

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8807860D0 (en) * 1988-04-05 1988-05-05 Connaught Lab Pertussis vaccine
ATE205534T1 (de) * 1988-12-16 2001-09-15 Nederlanden Staat Pneumolysin-mutanten und pneumokokken-impfstoffe daraus
DE4133707A1 (de) * 1991-10-11 1993-04-15 Behringwerke Ag Verfahren zur reinigung von streptolysin o, intaktes streptolysin o erhaeltlich nach diesem verfahren und seine verwendung
GB9216351D0 (en) * 1992-07-31 1992-09-16 Wellcome Found Vaccine production
US5565204A (en) * 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
WO1996023061A2 (en) * 1995-01-27 1996-08-01 Genencor International, Inc. Surfactant-based enzyme extraction process
US5877298A (en) * 1995-05-04 1999-03-02 Connaught Lab Acellular pertussis vaccines and methods of preparing thereof
US5667786A (en) * 1995-06-07 1997-09-16 Novavax, Inc. Method for treating tumors with a toxin
CA2297374A1 (en) * 1997-07-21 1999-01-28 North American Vaccine, Inc. Modified immunogenic pneumolysin, compositions and their use as vaccines
WO2000056360A2 (en) * 1999-03-19 2000-09-28 Smithkline Beecham Biologicals S.A. Vaccine against antigens from bacteriae
JP4132694B2 (ja) * 2000-03-10 2008-08-13 独立行政法人科学技術振興機構 受容体認識部位が保存された生理活性物質の誘導体及びその使用方法
GB0022742D0 (en) 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
RU2340627C2 (ru) * 2003-03-13 2008-12-10 ГлаксоСмитКлайн Байолоджикалз с.а. Способ очистки бактериального цитолизина
GB0421083D0 (en) 2004-09-22 2004-10-27 Glaxosmithkline Biolog Sa Purification process

Also Published As

Publication number Publication date
MXPA05009579A (es) 2005-11-17
US8815254B2 (en) 2014-08-26
EP1601689A2 (en) 2005-12-07
CA2812817C (en) 2016-12-20
NO336672B1 (no) 2015-10-19
HK1086013A1 (en) 2006-09-08
IS2587B (is) 2010-02-15
RU2005125832A (ru) 2006-04-27
JP2006520205A (ja) 2006-09-07
EG24449A (en) 2009-07-13
EP1601689B1 (en) 2007-11-28
ES2295836T3 (es) 2008-04-16
RU2340627C2 (ru) 2008-12-10
NO20054134D0 (no) 2005-09-06
CA2518669A1 (en) 2004-09-23
AU2004219910A1 (en) 2004-09-23
JP2010259448A (ja) 2010-11-18
AU2010212257B2 (en) 2012-08-30
JP5683866B2 (ja) 2015-03-11
CA2812817A1 (en) 2004-09-23
CY1107134T1 (el) 2012-10-24
IL210984A0 (en) 2011-04-28
KR20050111357A (ko) 2005-11-24
CN101818185B (zh) 2016-05-25
US8309327B2 (en) 2012-11-13
MA27666A1 (fr) 2005-12-01
NO20054134L (no) 2005-10-04
IS7993A (is) 2005-08-18
NZ541969A (en) 2008-01-31
KR101052996B1 (ko) 2011-07-29
JP4597123B2 (ja) 2010-12-15
DE602004010376T2 (de) 2008-10-23
CN101818185A (zh) 2010-09-01
US20140010843A1 (en) 2014-01-09
US20110311577A1 (en) 2011-12-22
BRPI0408094A (pt) 2006-02-14
US8084235B2 (en) 2011-12-27
DE602004010376D1 (de) 2008-01-10
CA2518669C (en) 2014-07-29
AU2010212257A1 (en) 2010-09-02
WO2004081515A3 (en) 2004-11-11
AU2004219910B2 (en) 2010-06-17
PT1601689E (pt) 2008-01-04
US20070026010A1 (en) 2007-02-01
WO2004081515A2 (en) 2004-09-23

Similar Documents

Publication Publication Date Title
DK1601689T3 (da) Oprensningsfremgangsmåde for bakterielt cytolysin
NO2016001I1 (no) Trastuzumab emtansin
ECSP066436A (es) Compuestos heterociclicos fusionados
SE0301569D0 (sv) Novel compounds
DK1605897T3 (da) Polyethelen-glycol-link-glp-1-forbindelser
DE50310488D1 (de) Längsträger
DK1524928T3 (da) Tandbørster
SE0301567L (sv) Robot system
DK1694705T3 (da) Interleukin-10-antistoffer
NO20055459D0 (no) Prosesser
ATE333815T1 (de) Zahnbürste
ATE453394T1 (de) Multipartikeln
IS8089A (is) Efnasambönd
DK1597007T3 (da) Borepatron
DE502004002283D1 (de) Pasteurisierungsanlage
NO20055097D0 (no) Krystallinske N-formyl-hydroksylaminforbindelser
NO20031736D0 (no) Forbindelser
ITVI20030028U1 (it) Raccordo per tubazioni
SI1601689T1 (sl) Cistilni postopek za bakterijski citolizin
SE0303206D0 (sv) Reningsanordning
SE0302667D0 (sv) Novel Compounds
SE0300388D0 (sv) Novel compounds
SE0300118D0 (sv) Novel Compounds
ITBZ20030062A1 (it) Doppiogancio fermacanne per la viticoltura
NO20035294D0 (no) Forbindelser